# Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

> **NCT01326364** · — · TERMINATED · sponsor: **Stanford University** · enrollment: 6 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **PROCEDURE:** Stereotactic body radiotherapy
- **DRUG:** Iodixanol
- **DRUG:** Iohexol

## Key facts

- **NCT ID:** NCT01326364
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01326364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01326364, "Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01326364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*